Home / Health / New Hair Loss Drug Offers Hope After Decades
New Hair Loss Drug Offers Hope After Decades
1 Jun
Summary
- A new extended-release oral minoxidil drug is in development.
- Clinical trials show significant hair growth in men within six months.
- The drug, VDPHL01, aims to improve upon existing topical treatments.
A biopharmaceutical company, Veradermics, is developing VDPHL01, an extended-release oral minoxidil specifically for androgenetic alopecia. This marks the first new drug for this common hair loss type since 1997. Current topical minoxidil treatments have drawbacks like messiness and frequent application, while oral minoxidil can cause unwanted body hair growth and blood pressure issues.
VDPHL01 utilizes microdosing and extended-release technology to offer a "sweet spot" of hair growth with reduced side effects. Initial clinical trials involving 519 men showed an average increase of 30 to 33 hairs per square centimeter over six months. Further trials are planned, including evaluations for women, with results expected later this year and enrollment currently underway for Phase three.
While VDPHL01 is still undergoing development and awaits approval, the prospect of a novel treatment, especially one addressing unmet needs for women, has generated significant excitement among experts. The drug aims to provide longer exposure to hair follicles, potentially leading to more consistent and rapid hair regrowth compared to immediate-release formulas.
